

Association of quantitative lung fibrosis (QLF) score with the severity and progression of progressive pulmonary fibrosis (PPF)



Aparna C Swaminathan,^{1,2} Timothy PM Whelan,³ Megan L Neely,^{1,2} Jamie L Todd,^{1,2} Scott M Palmer,^{1,2} Jeremy M Weber,¹ Grace H J Kim,⁴ Peide Li,⁵ Thomas B Leonard,⁵ Jonathan Goldin^{4,6} on behalf of the ILD-PRO Registry investigators

¹Duke Clinical Research Institute, Durham, North Carolina, USA; ²Duke University Medical Center, Durham, North Carolina, USA; ³Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; ⁴Department of Radiological Sciences, David Geffen School of Medicine, and Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, USA; ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA; ⁶Voiant Clinical LLC, Boston, Massachusetts, USA.

INTRODUCTION

- Progressive pulmonary fibrosis (PPF) is a term that is generally used to describe progressive lung fibrosis in patients with a fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF).¹
- The prognostic value of quantitative measures of lung fibrosis on high-resolution computed tomography (HRCT) in patients with PPF has not been established.

AIM

- To evaluate associations between quantitative scores derived from HRCT scans and the severity and progression of PPF in patients in the ILD-PRO Registry.

METHODS

The ILD-PRO Registry

- Patients enrolled in the ILD-PRO Registry had an ILD other than IPF, reticular abnormality and traction bronchiectasis (with or without honeycombing) on an HRCT scan and/or lung biopsy, and met criteria for ILD progression within the prior 24 months.² Patients were followed prospectively while receiving usual care.

HRCT

- HRCT images taken within the 24 months prior to enrollment or up to 90 days post-enrollment were analyzed using a machine learning algorithm^{3,4} to derive the following scores, expressed as percentages of total lung involvement:

- Quantitative lung fibrosis (QLF) (fibrotic reticulation patterns with architectural distortion)
- Quantitative ground glass (QGG)
- Quantitative honeycomb cysts (QHC)
- Quantitative ILD (QILD) (sum of QLF, QGG and QHC scores).

- Median (Q1, Q3) time from the HRCT scan to enrollment was 5.1 (2.2, 9.4) months.

Analyses


- Associations between tertiles of each quantitative HRCT score and measures of disease severity at enrollment were assessed using linear or ordinal proportional odds logistic regression.
- Associations between tertiles of each quantitative HRCT score at enrollment and ILD progression (relative decline in FVC % predicted $\geq 10\%$, lung transplant, or death) were analyzed using Cox proportional hazard models.

CONCLUSIONS

- Among patients with PPF in the ILD-PRO Registry, patients with worse QLF scores had worse disease severity at enrollment. Patients with worse QLF scores had a significantly increased risk of ILD progression during follow-up in unadjusted analyses, but not in analyses adjusted for sex, age and disease severity at enrollment. There were no significant associations between other HRCT-derived scores and the risk of ILD progression.
- These data support a structure-function relationship between the extent of fibrosis on HRCT and physiologic measures in patients with PPF.

RESULTS

Types of ILD



N=395. One patient had missing data.

Associations between QLF tertiles and measures of disease severity at enrollment

	Effect size for QLF tertile		
	Highest vs lowest tertile	Middle vs lowest tertile	P-value
FVC % predicted	-18.62 (-22.61, -14.63)	-9.71 (-13.65, -5.76)	<0.001
DLco % predicted	-17.49 (-20.99, -13.98)	-11.11 (-14.59, -7.62)	<0.001
GAP stage	9.13 (5.15, 16.21)	2.48 (1.51, 4.10)	<0.001
Oxygen use	10.39 (5.98, 18.05)	2.22 (1.26, 3.88)	<0.001

Cut-off for lowest tertile: <10.7%. Cut-off for highest tertile: $\geq 20.5\%$. Data for FVC % predicted and DLco % predicted are mean difference (95% CI). Data for GAP stage and oxygen use are odds ratio (95% CI) and parameterized as "worse" versus "better" health status.

Associations between QGG tertiles and measures of disease severity at enrollment

	Effect size for QGG tertile		
	Highest vs lowest tertile	Middle vs lowest tertile	P-value
FVC % predicted	-8.58 (-12.89, -4.27)	-6.99 (-11.27, -2.71)	<0.001
DLco % predicted	-5.94 (-9.89, -2.00)	-1.73 (-5.62, 2.16)	0.011
GAP stage	1.60 (0.97, 2.64)	1.36 (0.84, 2.23)	0.17
Oxygen use	2.38 (1.47, 3.88)	1.70 (1.04, 2.79)	0.002

Cut-off for lowest tertile: <18.5%. Cut-off for highest tertile: $\geq 28.0\%$. Data for FVC % predicted and DLco % predicted are mean difference (95% CI). Data for GAP stage and oxygen use are odds ratio (95% CI) and parameterized as "worse" versus "better" health status.

Associations between QHC tertiles and measures of disease severity at enrollment

	Effect size for QHC tertile		
	Highest vs lowest tertile	Middle vs lowest tertile	P-value
FVC % predicted	2.62 (-1.88, 7.12)	4.22 (-0.13, 8.58)	0.16
DLco % predicted	1.19 (-2.87, 5.25)	1.45 (-2.50, 5.39)	0.75
GAP stage	1.59 (0.96, 2.65)	1.52 (0.93, 2.48)	0.14
Oxygen use	1.44 (0.88, 2.36)	1.24 (0.77, 2.02)	0.34


Cut-off for lowest tertile: <0.02%. Cut-off for highest tertile: $\geq 0.48\%$. Data for FVC % predicted and DLco % predicted are mean difference (95% CI). Data for GAP stage and oxygen use are odds ratio (95% CI) and parameterized as "worse" versus "better" health status.

Associations between QILD tertiles and measures of disease severity at enrollment

	Effect size for QILD tertile		
	Highest vs lowest tertile	Middle vs lowest tertile	P-value
FVC % predicted	-16.76 (-20.84, -12.69)	-8.68 (-12.71, -4.66)	<0.001
DLco % predicted	-14.66 (-18.30, -11.01)	-8.34 (-11.98, -4.70)	<0.001
GAP stage	6.08 (3.52, 10.51)	2.08 (1.27, 3.41)	<0.001
Oxygen use	8.64 (5.04, 14.81)	2.39 (1.38, 4.13)	<0.001


Cut-off for lowest tertile: <32.2%. Cut-off for highest tertile: $\geq 51.4\%$. Data for FVC % predicted and DLco % predicted are mean difference (95% CI). Data for GAP stage and oxygen use are odds ratio (95% CI) and parameterized as "worse" versus "better" health status.

Unadjusted associations between tertiles of quantitative scores at enrollment and time to ILD progression



Median follow-up was 17.3 months; 133 patients (33.7%) had ILD progression.

Adjusted associations between tertiles of quantitative scores at enrollment and time to ILD progression



Adjusted for sex, age, FVC % predicted and oxygen use (at rest, with exertion, none) at enrollment. Median follow-up was 17.3 months; 133 patients (33.7%) had ILD progression.

REFERENCES


- Raghu G et al. Am J Respir Crit Care Med 2022;205:e18-e47.
- Lobo LJ et al. Poster presented at European Respiratory Society International Congress, 2023. Available at: <https://www.globalmedcomms.com/respiratory/ERS2023/Lobo>
- Kim H et al. Acad Radiol 2008;15:1004-16.
- Kim H et al. Clin Exp Rheumatol 2010;28(5 Suppl 62):S26-35.

ACKNOWLEDGEMENTS AND DISCLOSURES

The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this poster. Julie Fleming and Wendy Morris of Fleishman-Hillard provided editorial assistance, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. Aparna C Swaminathan is a faculty member of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to coordinate the IPF-PRO/ILD-PRO Registry. She also reports consulting fees from United Therapeutics.



Scan QR code or visit URL for a device-friendly version of this poster.



Scan QR code or visit URL for a webpage featuring BI-supported presentations at ATS 2024.



<https://www.usscicomms.com/respiratory/ATS2024/Swaminathan2>

<https://www.usscicomms.com/respiratory/ATS2024>

ILD-PRO Registry enrolling centers: Albany Medical Center, Albany, NY; Baylor College of Medicine, Houston, TX; Baylor University Medical Center at Dallas, Dallas, TX; Cleveland Clinic, Cleveland, OH; Duke University Medical Center, Durham, NC; Emory University, Atlanta, GA; Froedtert & The Medical College of Wisconsin Community Physicians, Milwaukee, WI; Houston Methodist Lung Center, Houston, TX; Lahey Clinic, Burlington, MA; Loyola University Health System, Maywood, IL; Lynchburg Pulmonary Associates, Lynchburg, VA; Medical University of South Carolina, Charleston, SC; Northwestern University, Evanston, IL; NYU Medical Center, New York, NY; Piedmont Healthcare, Austell, GA; Ponce Research Institute, Ponce, Puerto Rico; Pulmonix LLC, Greensboro, NC; Salem Chest and Southeastern Clinical Research Center, Winston Salem, NC; St. Joseph's Hospital, Phoenix, AZ; Stanford University, Stanford, CA; The Oregon Clinic, Portland, OR; Thomas Jefferson University, Philadelphia, PA; Tulane University, New Orleans, LA; UNC Chapel Hill, Chapel Hill, NC; University of Alabama at Birmingham, Birmingham, AL; University of California, Davis, Davis, CA; University of California Los Angeles, Los Angeles, CA; University of Chicago, Chicago, IL; University of Cincinnati Medical Center, Cincinnati, OH; University of Kansas, Lawrence, KS; University of Michigan, Ann Arbor, MI; University of Minnesota, Minneapolis, MN; University of Oklahoma, Norman, OK; University of Pennsylvania, Philadelphia, PA; University of Virginia, Charlottesville, VA; UT Southwestern Medical Center, Dallas, TX; Vanderbilt University Medical Center, Nashville, TN; University of Vermont Lung Center, Colchester, VT; Wake Forest University, Winston Salem, NC; Washington University, St. Louis, MO; Weill Cornell Medical College, New York, NY; Wilmington Health and PMG Research, Wilmington, NC; Yale School of Medicine, New Haven, CT.

Poster presented at the American Thoracic Society International Conference, 2024.